Market revenue in 2023 | USD 7,038.2 million |
Market revenue in 2030 | USD 18,653.9 million |
Growth rate | 14.9% (CAGR from 2023 to 2030) |
Largest segment | Tavr (transcatheter aortic valve replacement) |
Fastest growing segment | LAAC (Left Atrial Appendage Closure) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | SAVR (Surgical Aortic Valve Replacement), TAVR (Transcatheter Aortic Valve Replacement), Mitral Repair (Annuloplasty), LAAC (Left Atrial Appendage Closure) |
Key market players worldwide | Boston Scientific Corp, Medtronic PLC, Edwards Lifesciences Corp, Abbott Laboratories, St. Jude Medical, LivaNova PLC, Stryker Corp, Lepu Medical, Biomerics, CardioKinetix |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to structural heart devices market will help companies and investors design strategic landscapes.
Tavr (transcatheter aortic valve replacement) was the largest segment with a revenue share of 50.88% in 2023. Horizon Databook has segmented the U.S. structural heart devices market based on savr (surgical aortic valve replacement), tavr (transcatheter aortic valve replacement), mitral repair (annuloplasty), laac (left atrial appendage closure) covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. market for structural heart devices is anticipated to witness substantial growth in the coming years, propelled by the escalating prevalence of heart disease and associated conditions. According to the CDC, heart disease stands as the leading cause of death in the U.S., with an estimated 695,000 individuals dying due to heart disease.
In addition, the rising geriatric population and the widespread adoption of advanced technologies further drive market expansion. As people live longer, the incidence of CVDs amenable to these devices, such as aortic stenosis and mitral valve regurgitation, is expected to rise.
Projections from a report by the American College of Cardiology indicate that over 5 million Americans aged 65 and over are projected to have heart valve disease by 2035, underscoring the pressing need for innovative structural heart solutions.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. structural heart devices market , including forecasts for subscribers. This country databook contains high-level insights into U.S. structural heart devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account